

Streamlining Microfluidic Device Development through an Open-Source Compendium


Regul8ors

Sergio Garcia, Salome Ghvinephadze, Emily Reitz, Shivali Vashisht

December 4, 2024




Current Non-clinical Testing Platforms



Organ-on-Chip to Model Human Tissues

Microphysiological systems (MPS) are designed to mimic physiologically relevant functions of human tissues and can be more predictive than current *in vitro* and *in vivo* animal models¹



[2]

FDA Focus Area

Novel Technologies to Improve Predictivity of Non-clinical Studies and Replace, Reduce, and Refine Reliance on Animal Testing



Regulatory Significance of Alternative Testing Methods in Numbers:

There has been a 400% increase in medical device submissions that utilize microfluidics between
2013-2018

U.S. Food and Drug Administration. Microfluidics Program: Research on
Microfluidics-Based Medical Devices



Current Regulations

- **No specific FDA-recognized standards**
- The microfluidics program of CDRH actively engages in research and standardization efforts
- Since 2023: a collaboration between the FDA and the NCATS to advance MPS technologies

U.S. Food and Drug Administration. Memorandum of Understanding 225-23-003



The Microfluidics Program Activity

Target Areas

- Preclinical testing protocols
- Materials and microfluidic device manufacturing processes
- *In vitro* models representing common microfluidic device applications
- Impact of Microfluidic failure modes on device performance

Gaps

- Lack of understanding of performance failures
- Reliance on costly clinical data
- Challenges in translating research devices to commercial products
- “One size fits all” does not apply

U.S. Food and Drug Administration. Microfluidics Program: Research on Microfluidics-Based Medical Devices




Proposed Solution from Regulators

★ A Shared Compendium for MPS devices

- ★ Advancing expedited regulatory pathways for Diagnostic MPS Devices



Regulatory Science Solution



KEY FEATURES

Login-Based

Standard operating procedures

Curated Datasets

Performance Benchmarks

Case Studies

Regulatory Guidance

Community Features

Cross-Disease Models



MPS Compendium Streamlines Discovery

Cross-Disciplinary
Collaboration


FDA Standardization

Transparency

Reproducibility

Personalized Medicine


Accelerates Adoption of
MPS Approaches in
Regulatory Practice



MPS can be paired with human samples
and enable disease diagnostics



MPS Compendium could significantly support pathways like **Breakthrough Therapy Designation**, **Accelerated Approval**, and **Fast Track Designation** by enhancing the preclinical and translational stages of product development



Compendium challenges and workarounds

Challenges	Standardization of Data	Integration of Data from Multiple Disciplines	Data Confidentiality	Resource Maintenance	Reluctance toward participation
Workarounds	Develop flexible data templates that allow for the categorization of different types of MPS devices	Employ subject matter experts and FDA representatives to oversee and validate content	Implement encryption and access control	Partner with academic consortia, NIH, or industry to co-fund and manage the platform	Offer incentives to researchers for validating and contributing new MPS models



Summary

Focus Area

Novel Technologies to Improve Predictivity of Non-clinical Studies and Replace, Reduce, and Refine Reliance on Animal Testing

Main Challenge

No specific FDA-recognized standards for microfluidic devices

Proposed Solution

Open-Source MPS Compendium

Regulatory Impact

Accelerating the incorporation of microfluidic devices in diagnostics



Thank You!



References:

Ma, C. et al. *Trends Pharmacol Sci*, 2021.

Baran, S. W. et al. *ALTEX - Alternatives to Animal Experimentation*, 2022.

Ko, J. et al. *Adv. Healthcare Mater.*, 2024.

U.S. Food and Drug Administration. Focus Areas of Regulatory Science Report. [Accessed December 3, 2024]. Available at: <https://www.fda.gov/science-research/advancing-regulatory-science/focus-areas-regulatory-science-report>

U.S. Food and Drug Administration. Microfluidics Program: Research on Microfluidics-Based Medical Devices. [Accessed December 3, 2024]. Available at: <https://www.fda.gov/medical-devices/medical-device-regulatory-science-research-programs-conducted-osel/microfluidics-program-research-microfluidics-based-medical-devices#:~:text=Microfluidics%20Program%3A%20Research%20on%20Microfluidics%2DBased%20Medical%20Devices,-Subscribe%20to%20Email&text=The%20Microfluidics%20Program%20in%20the,that%20are%20safe%20and%20effective.>

U.S. Food and Drug Administration. Memorandum of Understanding 225-23-003. [Accessed December 3, 2024]. Available at: <https://www.fda.gov/about-fda/domestic-mous/mou-225-23-003>

Michael, D. T., et al. *Eur J Health Econ*, 2024.

